Cured giant hepatocellular carcinoma after transarterial embolization complicated with liver abscess formation✩✩

Malkhaz Mizandari, MD, PhDa,b, Tamta Azrumelashvili, MD, PhDb, Nino Toria, MDc, Nino Nanava, MDc, Ia Pantsulaia, PhDb, Nino Kikodze, PhDb, Nona Janikashvili, PhDb, Tinatin Chikovani, MD, PhDb,c,*

a Department of Diagnostic & Interventional Radiology of New Hospitals LTD, Tbilisi, Georgia
b Department of Radiology, Tbilisi state Medical University, Tbilisi, Georgia
c Department of Immunology, Tbilisi state Medical University, Street 33, Vazha-Pshavela Ave, Tbilisi, 0689, Georgia

A B S T R A C T

Many patients with hepatocellular carcinoma cannot be treated surgically because of the advanced stage of the tumor and/or coexisting cirrhosis. Transcatheter arterial embolization (TAE) represents an alternative therapeutic approach for some of these patients. However, it is not a curative measure, and an additional therapy is required to eradicate the residual disease.

In this communication, we report a case of 55-year-old man with giant hepatocellular carcinoma located in the right lobe of the liver that was successfully treated with TAE. TAE completely devascularized the tumor in one session. Despite of postembolization antibiotic therapy, complete tumor necrosis led to abscess formation. After 57 days of abscess drainage, necrotic tumor tissue was completely evacuated from the drained cavity; no viable tumor tissue was identified by computed tomography/magnetic resonance imaging scan on a 5 year follow-up.

TAE procedure can be suggested as a modulator of antitumor immune response, by exposing tumor antigens after necrosis leading to inflammation. In addition to necrosis caused by TAE, an antimicrobial acute inflammatory reaction in the treated area led to the complete destruction of the giant tumor.

© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington.
This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

A R T I C L E   I N F O

Article history:
Received 4 May 2020
Revised 1 June 2020
Accepted 2 June 2020

Keywords:
Transcatheter arterial embolization
Liver abscess
Hepatocellular carcinoma

✩ Declaration of Competing Interest: The authors have no conflicts of interest to declare.
✩✩ Acknowledgment: This research is funded by Shota Rustaveli National Science Foundation (Grant № PHDF-17-46).
* Corresponding author.
E-mail addresses: tinchikovani@gmail.com, tchikovani@tsmu.edu (T. Chikovani).
https://doi.org/10.1016/j.radcr.2020.06.008
1930-0433/© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, with over half a million new cases diagnosed annually worldwide. It represents the second leading cause of cancer related mortality in the world [1]. Classical treatments for HCC include surgical resection, liver transplantation, and local ablative therapy [2–4]. Fewer than 40% cases are operable, and the rate of tumor recurrence after curative surgery is high.

Microwave and radiofrequency ablation are the most widely used ablation technique, which is effective only for small metastatic and primary tumors [5,6]. Patients with intermediate stage multinodular disease without extrahepatic metastases and sufficient liver reserve should be offered transarterial therapies. It mainly includes transarterial chemoembolization (TACE) and transarterial embolization (TAE) – so called bland embolization. Transarterial therapy is now a validated treatment for unresectable HCC [7]. The latest National Comprehensive Cancer Network (NCCN) guidelines suggest that TACE should be considered as a frontline treatment for unresectable HCC with a diameter more than 5 cm. However, it is debatable whether TAE gives the same survival advantage as TACE [8–10].

TACE according this novel schedule is feasible and associated with a higher response rate than TAE alone. However, the survival benefit of TACE over TAE is not documented [7].

The risk of liver abscess after TACE appears to be related to the extent of liver infarction. While some degree of infarction in the necrotic affected area is probably inevitable, abscess formation is rare [11]. When abscess occurs, it is due to coloniza-
tion of necrotic tumor from either enteric organisms or from bacteria introduced exogenously during the procedure [12]. Up to 60% of organisms are Gram-positive [13].

Here, we report the case of an HCC patient treated with TAE complicated with the abscess formation. After abscess drainage the tumor had regressed and completely disappeared.

Case report/Case presentation

A 55-year-old Caucasian male patient presented with fatigue, weight loss, and dull right upper quadrant pain. Ultrasound and computed tomography (CT) scan revealed a giant (maximal diameter, 15 cm; volume, 1100 mL) inoperable right liver lobe hypervascular tumor with contrast wash-out in the venous phase (Fig. 1). Patient was anti-HCV-positive (with chemiluminescence immunoassay > 30) and alpha-fetoprotein was elevated (AFP– 11.68).

TAE was performed using 100-300 and 300-500 micron microparticles and sponge gel to the main feeder branches originating from the right hepatic artery and secondary feeders from the right inferior phrenic artery; Figure 2 shows the right

Fig. 1 – The initial CT scan (arterial phase; upper images axial–plane, lower images – saggital and coronal planes) shows giant (maximal diameter- 15 cm; volume- 1100 mL) hypervascular tumor in the right liver lobe. Main feeder – RHA (Yellow arrow), secondary feeder – right inferior phrenic artery (red arrow). (Color version available online.)
phrenic and right hepatic artery before and after bland embolization. TAE completely devascularized the tumor in one session, as shown by a postembolization CT scan (Fig. 3). The patient tolerated the embolization procedure without any early complications. Forty-five days after TAE, the patient returned to hospital with signs of infection: high fever (up to 39), chills and right upper quadrant abdominal pain. Blood tests revealed severe inflammation – white blood cell count showed $17.5 \times 109/L$, C-reactive protein level – 143 mg/L. In spite of postembolization antibiotic therapy, complete tumor necrosis led to abscess formation. A CT scan revealed 1550 mL of gas containing cystic mass – abscess (Fig. 4), which was drained under CT guidance using a 14Flocking loop catheter. Organoleptically purulent content was received, which may be the result of sterile inflammation caused by tumor necrosis, since no microorganisms were cultured. Abscess drainage was performed on an outpatient basis and was easily tolerated by the patient. AFP level was decreased to 2.43 (N <5.8) in few weeks. Fifty-seven days after drainage, necrotic tumor tissue was completely evacuated from the drained cavity; no viable tumor was identified at that moment on a follow-up CT scan (Fig. 5).

At a 5-year follow up, the patient was asymptomatic, without any signs of distress. He had normal liver tests, AFP was 3.17 (N <5.8) and no tumor recurrence was seen on follow-up magnetic resonance imaging (Fig. 6). After 6 years, health-related quality of life, evaluated by using the standard 4-item set of Healthy Days core questions (CDC HRQOL– 4), is excellent. This report demonstrates the full eradication of giant HCC documented by magnetic resonance imaging after the follow-up of 63 months after TAE procedure.

**Discussion/conclusion**

HCC has a 5-year survival rate of <5% and there are at least 1 million novel cases per year [14]. TAE/TACE is a widely accepted treatment option for unresectable HCC. The final goal of TAE treatment is to obtain complete necrosis of the malignant tissue by disruption of the blood supply to the tumor tissue.

TAE/TACE therapy may cause several major complications which include hepatic failure, liver abscess, liver rupture, biliary tract injury, renal failure, necrotizing pancreatitis, cerebral lipiodol embolism, and hepatic encephalopathy [15–18]. The reported mortality rates due to embolization complications range from 13.3% to 50% [19,20].
Liver abscess formation is a rare and potentially fatal complication of TAE/TACE. The incidence of post-TAE/TACE liver abscess for liver cancer varies from 0% to 1.1% according to the previous works [21–23]. The incidence of post-TAE/TACE liver abscess is statistically discrepant among different studies, which is likely attributed to the heterogeneous populations, variation in embolization treatment, and numbers of involved patients [24].

Effective management of liver abscess relies on a clear understanding of its pathogenesis, improvement of the diagnosis, clarification of its imaging characteristics, administration of sufficient doses of sensitive antibiotics in a timely manner, and active abscess cavity puncture aspiration and drainage [25]. Those with larger abscesses and those with more advanced age have worse outcomes [26].

Despite of its severe and fatal outcome abscess formation may lead to complete tumor resolution, according to previous studies [26, 27]. Among the 10 reported postremobilization liver abscess out of 3878 TAE procedures, one resulted in tumor shrinkage following abscess resolution (from 13 to 4 cm). Surgery was subsequently performed and the patient remained tumor free for a period of 4 years and 9 months after the operation before a small new growth was detected [26]. In the same study, another patient experienced total tumor regression after resolution of the abscess. He remained tumor free for the next 3 years and 7 months before new growth was detected. There is also a report of the patient who survived 5.5 years with a regressed giant HCC after TAE procedure complicated with liver abscess.

As an established notion, TAE destroys a tumor by the induction of necrosis and/or apoptosis and causes inflammation with cytokine production, which may favor immune activation and presentation of tumor-specific antigens [28], however, this effect is not sufficient for complete tumor resolution. Desirable outcome might be achieved synergizing TAE procedure with immunotherapeutic approaches [29].

For at least 2 centuries, there were reports that cancer patients infected with various bacteria demonstrated spontaneous remission [30]. Thus, bacteria or their extracts were further used in the treatment of cancer [31, 32]. Bacteria, their toxins or extracts can stimulate the immune system against tumors. Even more, Bacteria can directly attack and eradicate tumors by invading cancer cells [33].

Streptococcal preparation OK-432 has been used as antitumor agent for more than 20 years, and its safety is well established [34, 35]. OK-432 promotes the functional maturation of mIL-4-DC through ligation of TLR4 [36] and TLR9 [37], and this maturation correlates with the upregulated expression of CD80, CD83, and CD86, thus promoting the effective induction of antigen-specific T cells [37]. It is also reported that following OK-432 activation, human mIL-4-DCs can specifically kill tumor cells via a novel CD40/CD40 ligand-mediated mechanism, without affecting normal cells [38].

In the case reported herein, an accidental infection of the tumor, following TAE procedure can be suggested as a modulator of antitumor immune response, by exposing tumor antigens after necrosis leading to inflammation. In addition to necrosis caused by TAE, the microbes generate an antimicrobial inflammatory response and a severe acute inflammatory
reaction. A strong immune response, caused by necrosis and an infectious agent, led to the complete destruction of the giant tumor. Thus, this procedure became curable.

Complete removal of cancer without damage of normal tissues, which is the ideal performance of cancer treatment, has been achieved with the formation of a liver abscess after TAE. TAE induced a tumor-specific immune response and infection probably acted as adjuvant therapy that enhanced the anti-tumor effect of TAE procedure. As a result, a combination of these processes led to the complete destruction of the tumor. Exploration of the underlying mechanism behind this rare phenomenon might be cardinal to find curative treatments for advanced cancer.

The study protocol was approved by Tbilisi State Medical University ethical committee on human research. The patient has given her written informed consent to publish their case (including publication of images).

**Author contributions**

MM and TA performed all medical procedures and patient monitoring. MM and TC designed the report. NT and NN collected and analyzed the data. IP, NK and TC wrote the manuscript. NJ edited the manuscript.

**Statements**

**Statement of Ethics:** The case are presented in accordance with the World Medical Association Declaration of Helsinki.
Fig. 5 – CT follow-up.

Fig. 6 – Follow-up MRI after TAE (5 years after treatment). No recurrence of liver tumor.
REFERENCES

[1] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245–55.

[2] Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Supplement 4):iv238–55.

[3] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020–2.

[4] Gao ZH, Bai DS, Jiang GQ, Jin SJ. Review of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma. World J Hepatol 2015;7(1):40–3.

[5] Lee MW, Kang D, Lim HK, Choj, Sinn DH, Kang TW, et al. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol. 2020. doi:10.1007/s00330-019-06575-0.

[6] Correa-Gallego C, Fong Y, Conen M, D’Angelica M I, Allen P J, De Matteo R P, et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol 2014;21:4278–83.

[7] Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 2013;108(6):1252–9.

[8] Lovet JM, Real M I, Montana X, Coll S, Aponte J, Ayuso C, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9291):1734–9.

[9] Chang JM, Tseng WS, Pan HB, Yang VF, Lai KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer. 1994;74(9):2449–53.

[10] Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1992;31(Suppl):S1–6.

[11] Gates J, Harnell GG, Stuart KE, Clouse ME. Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 1999;19(2):399–414.

[12] Cohen SE, Safadi R, Verstandig A, Sasson T, Simmer L, Shouval D. Liver-spleen infarcts following transcatheter chemoembolization: a case report and review of the literature on adverse effects. Dig Dis Sci 1997;42(5):938–43.

[13] Chen C, Chen PJ, Yang PM, Huang GT, Lai MY, Tsang MY, et al. Clinical and microbiological features of liver abcess after transarterial embolization for hepatocellular carcinoma. Am J Gastroenterol 1997;92(12):2257–9.

[14] Motola-Kuba D, Zamora-Valdez D, Uribe M, Mendez-Sanchez N. Hepatocellular carcinoma. An overview. Ann Hepato 2006;5(1):16–24.

[15] Bae SJ, Yeon JE, Lee JM, Kim JH, Lee HJ, Lee SJ, et al. A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma. Clin Mol Hepatol 2012;18(3):321–5.

[16] Chu HJ, Lee CW, Yeh SJ, Tsai IK, Tang SC, Jeng JS. Cerebral lipiodol embolism in hepatocellular carcinoma patients treated with transarterial embolization/chemoembolization. PLoS One 2015;10(6):e0129367.

[17] Tbro A, Bertino G, Arcerito MC, Mannino M, Arditi A, Patane D, et al. A lethal complication after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. Case Rep Surg 2015;2015:873601.

[18] Jia Z, Tian F, Jiang G. Ruptured hepatic carcinoma after transcatheter arterial chemoembolization. Curr Ther Res Clin Exp 2013;74:41–3.

[19] Sun Z, Li G, Ai X, Luo B, Wen Y, Zhao Z. Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. Crit Rev Oncol Hematol 2011;79(2):164–74.

[20] Chen C, Chen PJ, Yang PM, Huang GT, Lai MY, Tsang MY, et al. Clinical and microbiological features of liver abcess after transarterial embolization for hepatocellular carcinoma. Am J Gastroenterol 1997;92(12):2257–9.

[21] Chen C, Tsang YM, Huah P, Huang GT, Yang PM, Sheu JC, et al. Bacterial infections associated with hepatic arteriography and transarterial embolization for hepatic carcinoma: a prospective study. Clin Infect Dis 1999;29(1):161–6.

[22] Kim W, Clark TW, Baum RA, Soulen MC. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001;12(8):965–8.

[23] Ly WF, Lu D, He YS, Xiao JK, Zhou CZ, Cheng DL. Liver abscess formation following transarterial chemoembolization: clinical features, risk factors, bacteria spectrum, and percutaneous catheter drainage. Medicine (Baltimore) 2016;95(17):e5035.

[24] Johnson GE, Ingraham CR, Nair AV, Padia SA. Hepatic abscess complicating transarterial chemoembolization in a patient with liver metastases. Semin Interv Radiol 2011;28(2):193–197.

[25] Sun W, Xu F, Li X, Li C-R. A case series of liver abscess formation after transcatheter arterial chemoembolization for hepatic tumors. Chin Med J 2017;130(11):1314–19.

[26] Ong G-Y, Changchien C-S, Lee C-M, Wang JH, Tung HD, Chuh S K, et al. Liver abscess complicating transcatheter arterial embolization: a rare but serious complication. A retrospective study after 3878 procedures. Eur J Gastroenterol Hepatol 2004;16(8):737–42.

[27] Chuh SK, Tai DS, Changchien CS, Lin DY, Chiu KW, Chen JJ, et al. Long term survival of a patient with a regressed giant hepatocellular carcinoma after transcatheter hepatic artery embolization (TAE) complicated with liver abscess. Changgeng Yi Xue ZaZhi 1994;17(1):68–73.

[28] Nakamoto Y, Mizukoshi E, Tsuji H, Sakai Y, Kitahara M, Ara K, et al. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol 2007;147(2):296–305.

[29] Ding M, Wang Y, Chi J, Tang X, Cui D, Qian Q, et al. Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients. PLoS ONE 2016;11(12):e0168798.

[30] Hoffman RM, Zhao M. Methods for the development of tumor-targeting bacteria. Expert Opin Drug Discov 2014;9(7):741–50. doi:10.1517/17440441.2014.916270.

[31] Coley WB. The Treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med 1910;3(Surg Sect):1–48.

[32] Tsung K, Norton JA. Lessons from Coley’s toxin. Surg Oncol 2006;15(1):25–8. https://doi.org/10.1016/j.suronc.2006.05.002.

[33] Jain RK, Forbes NS. Can engineered bacteria help control cancer? Proc Natl Acad Sci USA 2001;98(26):14748–50.
[34] Maehara Y, Okuyama T, Kakeji Y. Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 1994;168(1):36–40.

[35] Sato M, Yoshida H, Yanagawa T, Yura Y, Urata M, Atsumi M, et al. Effect of intradermal administration of streptococcal preparation OK-432 on interferon and natural killer cell activities in patients with oral cancer. Int J Oral Surg. 1984;13(1):7–15.

[36] Okamoto M, Oshikawa T, Tano T, Ohe G, Furuichi S, Nishikawa H, et al. Involvement of Toll-like receptor 4 signaling in interferon-γ production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst 2003;95(4):316–26.

[37] Oshikawa T, Okamoto M, Tano T, Sasai A, Kan S, Moriya Y, et al. Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent. J Immunother 2006;29(2):143–50.

[38] Hill KS, Errington F, Steele LP. OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions. J Immunol 2008;181(5):3108–15.